Viavi Solutions stock hits 52-week high at $35.63

Viavi (VIAV) hit a 52-week high of $35.63 with a market capitalization of $8.14B, delivering a 185.56% total return over the past year and a 173% gain over the last six months. Seven analysts raised earnings estimates and analysts expect the company to be profitable this year after a trailing-12-month loss, while InvestingPro flags the stock as potentially overvalued and Stifel reiterated Buy with a $35 price target. Viavi launched the Observer Threat Forensics tool (integrating CrowdStrike intelligence) and the TestCenter D2 1.6T appliance targeting AI networking for cloud providers and network equipment makers, and showcased its AI infrastructure validation portfolio at OFC 2026, underpinning its strategic positioning in AI networking and Aerospace & Defense.

Analysis

Vendors that provide high‑fidelity validation and fiber/optical test gear stand to capture outsized content-per-system as switch and NIC vendors push >1Tb interfaces into production; this increases bill‑of‑materials for hyperscalers and creates a multi‑quarter revenue cadence tied to design‑win conversion rather than spot orders. Optical component and SerDes test suppliers are the natural upstream beneficiaries — watch capacity for high‑speed test ASICs and automated inspection tooling as a potential bottleneck that can amplify vendor pricing power for 3–9 months.

On the demand side, the revenue inflection is lumpy: expect meaningful signals in quarterly bookings and backlog conversion over a 3–12 month window, while sustainable margin expansion requires both scale and services/recurring software attach. Major downside catalysts that would reverse the move are an AI capex pause at hyperscalers (material within 6–12 months), accelerated price competition from entrenched test incumbents, or missed design‑wins that push expected revenue into later fiscal years.

The market is pricing growth; the key second‑order risk is customer concentration and the stickiness of new software/security telemetry offerings — if those products fail to drive recurring ARR, multiples re‑rate quickly. That makes structured exposure preferable to naked equity exposure: capture upside from design‑win momentum while protecting against binary execution or macro capex shocks over the next 6–18 months.

Key Decisions for Investors

• Long VIAV equity with downside protection — buy VIAV shares and purchase 9–12 month OTM puts (~20% OTM) sized 40–50% of position to cap downside; target +35–45% in 12 months if design‑wins convert, stop if puts rise >2x (implied >20% realized risk).
• Call‑spread LEAP (lower cash outlay, defined risk) — buy 12–18 month VIAV LEAP call and sell a higher strike to fund premium (aim for 2.5–3.5x upside vs cost); entry after next quarterly guide confirms bookings cadence (~3–6 months).
• Relative value pair: long VIAV / short SPT (or EXFO) 6–18 months — size short 50% of long to isolate product‑mix and AI‑validation exposure; objective 20–30% spread capture if VIAV wins translate to share gains, risk if incumbents defend on price.
• Hedge/contrarian: small short on security vendor (CRWD) as a hedge to narrative risk — maintain <25% notional vs VIAV long, horizon 6–12 months; rationale is network‑telemetry synergies are often priced ahead of realized ARR and regulatory/implementation friction can delay monetization.